CSIMarket Company Name, Ticker, Suppliers, else..
 
Orchestra Biomed Holdings Inc   (NASDAQ: OBIO)
Other Ticker:  
 
 
Price: $3.0100 $0.02 0.669%
Day's High: $3.13 Week Perf: -4.75 %
Day's Low: $ 3.01 30 Day Perf: 3.79 %
Volume (M): 251 52 Wk High: $ 8.87
Volume (M$): $ 755 52 Wk Avg: $5.07
Open: $3.06 52 Wk Low: $2.37



 Market Capitalization (Millions $) 115
 Shares Outstanding (Millions) 38
 Employees 11
 Revenues (TTM) (Millions $) 3
 Net Income (TTM) (Millions $) -66
 Cash Flow (TTM) (Millions $) -5
 Capital Exp. (TTM) (Millions $) 0

Orchestra Biomed Holdings Inc
Orchestra Biomed Holdings Inc is a medical device company that focuses on the development and commercialization of innovative therapies for the treatment of cardiovascular diseases. The company is dedicated to developing advanced solutions for patients suffering from various cardiac conditions, including heart failure and heart attacks.

Orchestra Biomed Holdings Inc is known for its proprietary technology called the Virtue sirolimus-eluting balloon, which is designed to deliver targeted drug therapy to the diseased blood vessels. This technology aims to improve the effectiveness and safety of interventional cardiovascular procedures, providing better outcomes for patients.

The company's mission is to advance the field of cardiovascular medicine by developing groundbreaking therapies that address the unmet needs of patients. Through their research and development efforts, Orchestra Biomed Holdings Inc aims to revolutionize the treatment of cardiovascular diseases and ultimately improve the quality of life for patients worldwide.

Overall, Orchestra Biomed Holdings Inc is a medical device company that specializes in developing innovative therapies for cardiovascular diseases, with a focus on improving patient outcomes and advancing the field of cardiovascular medicine.


   Company Address: 150 Union Square Drive New Hope 18938 PA
   Company Phone Number: 862-5797   Stock Exchange / Ticker: NASDAQ OBIO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -2.06%    
BDX   -2.2%    
BSX        1.56% 
EW   -1.76%    
SYK   -0.46%    
TFX   -1.35%    
• View Complete Report
   



Orchestra Biomed Holdings Inc

Orchestra BioMed Holdings Inc Faces Revenue Decline in First Quarter of 2024

During the past 5 days, Orchestra BioMed Holdings Inc stock experienced a significant drop of -10.11%, leading to a year to date performance of -46.36%. Additionally, the stock is currently trading only 11.6% above its 52-week low. These figures paint a challenging picture for investors and highlight some concerning trends in the company's financial performance.
In the first quarter of 2024, Orchestra BioMed Holdings Inc declared disappointing financial results. The company experienced a remarkable decline in revenue, with a decrease of -46.735% to $0.62 million. Furthermore, the Medical Equipment & Supplies company posted a net deficit per share of $-0.38, compared to $-0.40 in the same period the year before. This decline in revenue contrasts with the overall performance of the Medical Equipment & Supplies sector, which experienced a top-line gain during the same period.
The previous financial reporting period had also shown negative results, with a net loss per share of $-0.23 and a significant increase in revenue by 136.641% from $0.26 million. However, this recent quarter's earnings season proved even more challenging for Orchestra BioMed Holdings Inc, as it realized a net loss of $-13.463 million, which was higher than the $-10.940 million loss the previous year.
Announcement

Orchestra BioMed to Unveil Breakthrough Hypertensive Pacemaker Therapy Program at In-Person R&D Day in New York

Published Tue, Apr 30 2024 12:01 PM UTC

Orchestra BioMed Holdings, an innovative biomedical company, has announced that it will be hosting an exclusive in-person Research and Development (R&D) day on June 11, 2024, at the prestigious Lotte New York Palace Hotel. The event will provide a platform for Orchestra BioMed to showcase their pioneering AVIM Therapy Program, specifically designed for hypertensive pacemaker...
Orchestra Biomed Holdings Inc

Orchestra BioMed Holdings Inc. Achieves Significant Milestone with $0.262 Million Revenue in Q4

Orchestra BioMed Holdings, Inc. is a biomedical company that is dedicated to bringing high-impact technologies to patients through partnerships that share both the risks and rewards. Recently, the company conducted a clinical study to evaluate the efficacy of Atrioventricular Interval Modulation (AVIM) therapy, also known as BackBeat CNT, in pacemaker-indicated patients with uncontrolled hypertension.
The study aimed to compare AVIM therapy with standard right ventricular (RV) pacing in terms of systolic blood pressure and overall cardiac function. The results of this pressure-volume (PV) loop study, conducted at Na Homolce Hospital in Prague under the supervision of Prof. Petr Neuil, M.D., were presented at the Technology and Heart Failure Therapeutics (THT) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D., Medical Director at LANS Cardio Hamburg.
Clinical Study

Atrioventricular Interval Modulation (AVIM) Therapy Demonstrates Favorable Hemodynamic Effects in Hypertensive Pacemaker Patients

Published Wed, Mar 6 2024 1:37 PM UTC

Orchestra BioMed Holdings, Inc. recently conducted a clinical study to evaluate the efficacy of Atrioventricular Interval Modulation (AVIM) therapy, also known as BackBeat CNT, in pacemaker-indicated patients with uncontrolled hypertension. The study aimed to compare AVIM therapy with standard right ventricular (RV) pacing in terms of systolic blood pressure and overall card...
Clinical Study

Evaluating the Efficacy and Safety of Atrioventricular Interval Modulation Therapy for Hypertensive Pacemaker Patients: The BACKBEAT Pivotal Study

Published Mon, Jan 8 2024 12:30 PM UTC

- Hypertension remains a significant global health concern, affecting millions of individuals worldwide.- Conventional pharmacological therapies for hypertension may not always effectively control blood pressure in certain patient populations, including those with pacemakers.- Orchestra BioMed Holdings, Inc. has initiated the BACKBEAT pivotal study to evaluate the potential ...






Orchestra Biomed Holdings Inc's Segments
Collaborative Arrangement Terumo    1777.42 % of total Revenue
Partnership revenue    84.33 % of total Revenue
Product revenue    15.67 % of total Revenue
Single Reportable Segment    5.07 % of total Revenue
Single Reportable Partnership revenue    84.33 % of total Revenue
Single Reportable Product revenue    15.67 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com